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Abstract
Glycans are essential regulators of protein function and are now in the focus of research in many physiological and
pathophysiological processes. There are numerous modes of regulating their biosynthesis, including epigenetic
mechanisms implicated in the expression of glyco-genes. Since N-glycans located at the cell membrane define intercellular
communication as well as a cellular response to a given environment, we developed a method to preferentially analyze this
fraction of glycans. The method is based on incorporation of living cells into polyacrylamide gels, partial denaturation of
membrane proteins with 3 M urea and subsequent release of N-glycans with PNGase F followed by HPLC analysis. Using this
newly developed method, we revealed multiple effects of epigenetic inhibitors Trichostatin A, sodium butyrate and
zebularine on the composition of N-glycans in human cells. The induced changes were found to be reversible after inhibitor
removal. Given that many epigenetic inhibitors are currently explored as a therapeutic strategy in treatment of cancer,
wherein surface glycans play an important role, the presented work contributes to our understanding of their efficiency in
altering the N-glycan profile of cancer cells in culture.
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Introduction
Glycans (oligosaccharide chains) play important roles in diverse
cellular functions of all eukaryotic cells. By attaching to backbones
of numerous membrane and soluble proteins they induce
structural changes, thereby regulating and modifying protein
function. Functional consequences of alternative glycosylation of a
particular protein can be drastic, as exemplified by the case of
immunoglobulin G. Here, the attachment of a single additional
monosaccharide can lead to various outcomes, including conver-
sion of IgG from pro-inflammatory into an anti-inflammatory
agent [1] or activation of pathways implicated in various
inflammatory diseases [2,3]. Even though functional aspects of
glycosylation of other proteins are less well understood, the
importance of glycosylation in the regulation of biological activity
of many other signaling and receptor proteins is certain. Amongst
others, these are Notch, GLUT4 and NMDA receptor, whose
glycosylation appears to play an important part in adaptive
regulation of the cell surface in cell-cell adhesion and cellular
communication [4].
Biosynthesis of glycan and polypeptide parts of a glycoprotein is
different. Contrary to polypeptide moieties, glycan moieties of
glycoproteins are not synthesized from the direct genetic template.
Instead, glycan structures result from the activity of a dynamic
network of over 600 glyco-genes [5] that code for various
glycosyltransferases, glycosidases, enzymes for sugar nucleotide
biosynthesis, transporters, etc. [6,7]. Glycan biosynthesis can also
be influenced by modulation of gene expression through
epigenetic mechanisms as well as a change in the activity and/
or the localization of any of the enzymes and various transcription
factors, proton pumps, and other proteins involved in this complex
pathway.
Epigenetic regulation of expression of glyco-genes is an obvious
mechanism which can explain both the temporal stability of the
glycome in healthy individuals [8] as well as specific changes which
were reported to appear in various diseases [9,10]. The number of
studies on epigenetic factors involved in protein glycosylation is
still limited [11,12]. Nevertheless, ones that link epigenetics to
glycosylation, mostly reporting aberrant glycosylation events in
cancer [13 and ref herein], emphasize the importance of
epigenetic factors in the regulation of protein glycosylation. For
instance, promoter methylation was shown to regulate the
expression of various glyco-genes, including a1,3-N-acetylgalacto-
saminyltransferase, an enzyme responsible for expression of the A
determinant in the blood group A [14]; N-acetylglucosaminyl-
transferases GnT-IVa and GnT-IVb in pancreas [15]; a-1,3/4
fucosyltransferase (FUT) 3 in gastric carcinoma cell lines [16] and
FUT7 in leukocytes [17]. Similarly, histone acetylation proved
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essential in the control of gene expression of a2,6 sialyltransferase
(ST6GalNAc6), involved in the expression of sialyl Lewisa antigen
in cancers of the digestive organs, where it serves as a ligand for E-
selectin, thus mediating metastasis [18].
The above-mentioned studies focus as well on the ability of
various epigenetic inhibitors to restore the function of genes,
silenced by aberrant epigenetic changes. It is this feature that
makes them interesting candidates in epigenetic therapy. The most
well known are the inhibitors of enzymes that establish and
maintain DNA methylation patterns (DNA methyltransferases,
DNMTs) and inhibitors of histone deacetylases (HDACs), which
remove acetyl groups mostly from lysines of histones H3 and H4.
Zebularine is a highly stable hydrophilic DNA methylation
inhibitor [19], which preferentially depletes DNA methyltransfer-
ase 1 (DNMT1), as demonstrated in bladder, prostate, lung, colon,
and pancreatic carcinoma cell lines [20], often resulting in
inhibition of cell proliferation and induction of apoptosis
[21,22]. These effects are probably related to reactivated
expression of epigenetically silenced genes both in carcinoma cells
in vitro [21,23,24], as well as in tumors grown in mice [23,25].
Zebularine exhibits low toxicity in mice even after prolonged
administration [19,26] and is the first in its class that can reactivate
an epigenetically silenced gene by oral administration [23]. On the
other hand, treatments of proliferating mammalian cells with
deacetylase inhibitor Trichostatin A (TSA; [27]) induced various
effects, including an increase in global H3K9 acetylation levels
[28], relocation of pericentric heterochromatin towards the
nuclear periphery [29], reactivation of growth-inhibiting genes
[30] and altered expression of numerous glycan structures [31].
Even though 3 days long recovery from TSA treatment can result
in complete restoration of histone acetylation levels, some induced
changes were irreversible suggesting the existence of some type of
epigenetic memory [32]. Another deacetylase inhibiting agent is
sodium (Na)-butyrate, a non-toxic short-chain fatty acid. It has
multiple effects on cultured mammalian cells including inhibition
of proliferation, induction of differentiation and induction or
repression of gene expression [33]. Interestingly, its strong
proapoptotic action is reported in various types of cancer [34].
De-regulation of glycosylation was reported to occur in a wide
range of diseases, including cancer, diabetes, cardiovascular,
congenital, immunological and infectious disorders. By using
limited glycoprofiling tools available to date, glycomic studies have
revealed medically useful glycan biomarkers for cancer and other
diseases [35–38]. Recently, we performed the first large-scale study
of the human plasma glycome which revealed very high variability
in the composition of plasma glycome in the population [39] and
identified individuals having significantly aberrant glyco-pheno-
types, some of which could be associated with specific diseases
[40]. To test potential therapeutic usefulness of epigenetic
inhibitors TSA, sodium butyrate and zebularine in inducing a
reversal of undesired glyco-phenotypes, we developed an HPLC-
based method for the determination of glycan structures from cells
embedded in polyacrylamide gels. In addition, we specifically
investigated the preservation of altered glycan profiles over a
prolonged period of time in a drug-free environment. Our results
emphasize the importance of epigenetic control in the regulation
of N-glycosylation, but also suggest the stability of complex
biosynthetic pathways responsible for the establishment of glycan
profiles in human cells in culture.
Materials and Methods
Cell culture techniques and immobilization in
polyacrylamide gel blocks
Human HeLa cell line (ATCC) was a kind donation of Dr.
Marie-Lise Lacombe, Faculty of Medicine St. Antoine, Paris. Cells
were cultured in Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogene) supplemented with 10% fetal bovine serum (FBS;
Sigma Aldrich), 200 mM glutamine, 100 U/ml penicillin and
100 mg/mL streptomycin in humidified chamber with 5% CO2 at
37uC.
The cells (86105) were seeded in 35 mm cell culture plate and
grown to confluence. Cells were detached with 1 mM EDTA,
washed 3 times in phosphate buffered saline (PBS) and during the
subsequent steps kept on ice. For cells lysate preparation the cells
were treated with lysis buffer (25 mM Tris-HCl pH 7.5, 1%
CHAPS, 5 mM EDTA), sonicated and dialyzed against 20 mM
NH4HCO3. Vacum dried samples were mixed with reduction
buffer (10 mM Tris-HCl pH 6.6, 40 mM DTT, 0.33% SDS) and
incubated for 15 min at 65uC in order to reduce disulfide bonds.
After reduction samples were alkylated by addition of 2 mL of
100 mM iodoacetamide (Sigma) and incubated for 30 min at RT
in dark. Prepared samples were embedded in 70.5 ml of
polyacrylamide gel (19.15% acrylamide:bisacrylamide 37.5:1,
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Figure 1. Contributions of individual glycan groups (GP1-GP12) to the cell membrane N-glycome. Contributions of mannose-bearing
glycans within each individual group are colored in orange.
doi:10.1371/journal.pone.0054672.g001
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478 mM Tris pH 8.8, 0.3% SDS, 0.3% APS, 1.5% TEMED). For
the immobilization of intact cells, the cells were resuspended in
70 mL of polyacrylamide gel (18.5% acrylamide:bisacrylamide
29.2:0.2, 375 mM Tris-HCl pH 7.5, 3 M urea, 0.1% APS, 1.5%
TEMED) and left to polymerize on ice between 1 and 2 minutes.
Immunocytochemistry and confocal scanning
microscopy of embedded cells
For confocal scanning microscopy the cells were embedded in
polyacrylamide and fixed in 4% formaldehyde, washed 3–4 times
in TBS (50 mM Tris, 150 mM NaCl, pH 7.4) and incubated with
Biotinylated Ricinus Communis Agglutinin I (5 mg/ml; Vector
Labs) in TBS over night, at 4uC. After incubation, gel was washed
three times in TBS and incubated 1 h with Streptavidin-PE
(0,125 mg/ml, BD Biosciences) in dark at RT. Gel was washed
three times with TBS, mounted on a slide and covered with a
coverslip. Fluorescent images were obtained using Leica TCS SP2
AOBS laser scanning confocal microscope equipped with HCXPL
APO l-Blue 6361.4 objective.
Glycan release and labeling
Gels were transferred into wells of UNIFILTER protein
precipitation (PP) fast flow (FF) plate (Whatman, 96 well plate,
2 ml, glass polypropylene). 1 ml of acetonitrile was added to the
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Figure 2. Composition of membrane and cell lysate N-glycomes. A. Glycans released from either HeLa cells embedded in polyacrylamide gels
(H) or HeLa cell lysates (HL) were labeled with 2-AB and separated by HPLC. The histogram shows the partition (percentage + SD) of individual glycan
fractions (GP1 – GP12) of HPLC separated glycome. B. Coefficients of variation (%CV) of individual glycan peaks in HPLC separated glycome of HeLa
cells embedded in polyacrylamide gels (H) and HeLa cell lysates (HL) from 6 identical experiments.
doi:10.1371/journal.pone.0054672.g002
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wells and after 10 min of shaking, the liquid was vacuumed to
waste. The washing procedure has been continued with 20 mM
NaHCO3, ACN, 20 mM NaHCO3, and finished with ACN.
UNIFILTER PP FF plate was then placed on a clean collection 96
well plate and gels were soaked with 1 ml of PNGase F (ProZyme
N-glycanase; Peptide-N-glycosidase F 2.5 U/ml) diluted in 99 ml of
20 mM NaHCO3. Gels were covered with another 50 ml of
20 mM NaHCO3, sealed with adhesive sealing film and left to
incubate for 18 h at 37uC. Samples which were left untreated with
PNGase F were incubated with 100 ml of 20 mM NaHCO3 and
further analysis has been performed as for PNGase F treated
samples.
Released N-glycans were eluted from gels by washing with
200 ml water, shaking for 10 min, and collecting the liquid to the
collection plate. The procedure was repeated two more times, and
continued with 200 ml of ACN, 200 ml of water, and finished with
200 ml of ACN. Released N-glycans were then dried in vacuum
centrifuge and fluorescently labeled with 2-aminobenzamide as
described by Royle et al. [41]. Labeled glycans were dried in
vacuum centrifuge and re-dissolved in known volume of water for
further analysis.
Hydrophilic interaction high performance liquid
chromatography (HILIC)
Released glycans were subjected to hydrophilic interaction high
performance liquid chromatography (HILIC) on a 25064.6 mm
i.d. 5 mm particle packed TSKgel Amide 80 column (Tosoh
Bioscience, Stuttgart, Germany) at 30uC with 50 mM formic acid
adjusted to pH 4.4 with ammonia solution as solvent A and
acetonitrile as solvent B. 60 min runs were performed with
fluorescence detector set with excitation and emission wavelengths
of 330 and 420 nm, respectively. The system was calibrated using
an external standard of hydrolyzed and 2-AB-labeled glucose
oligomers from which the retention times for the individual
glycans were converted to glucose units (GU).
Exoglycosidase sequencing of glycans
The following enzymes, all purchased from ProZyme (CA,
USA), were used for digestions: Sialidase ATM/NANase III
(recombinant gene from Arthrobacter ureafaciens, expressed in E.
coli), 2.5 mU; a(1–2,3,4,6)fucosidase (bovine kidney), 1.16 mU;
a(1–3,4)-fucosidase (almond meal), 3.2 mU; b(1–3,4)-galactosidase
(bovine testis), 5 mU; b-N acetylhexosaminidase/HEXase I
(recombinant gene from Streptococcus pneumoniae, expressed in E.
coli), 40mU; a(1–2,3,6)-mannosidase (jack bean), 300 mU. Ali-
quots of the 2-AB labeled glycan pool were dried down and
digested in a mixture of enzymes, corresponding 1X concentrated
manufacturers buffer and water in total volume of 5 ml. After
overnight incubation at 37uC, enzymes were removed by filtration
through the AcroPrep 96 Filter Plates, 10K (Pall Corporation, MI,
USA). Digested glycans were then separated by HILIC-HPLC for
comparison against an undigested equivalent.
For HPLC analysis of mannosidase digested and non digested
PNGase F free sample, we included an internal standard in order
to equalize and normalize peak signals, correctly interpret
background signals and verify the composition and percentages
of oligomannose structures within these peaks. 2-aminobenzamide
labeled dextran peak (120 000 glucose units), was added to both
samples in equal amounts before enzyme removal by filtration
trough AcroPrep 96 Filter Plates, 10K (Pall Corporation, MI,
USA) and HPLC analysis. In this chromatography period we did
not previously detect chromatography peaks in PNGase F free
Figure 3. Enzymatically untreated HeLa cells embedded in
polyacrylamide gels release glycan structures. Confocal images
of HeLa cells embedded in polyacrylamide gel. The peripheral cellular
glycans are stained with Ricinus Communis Agglutinin I. Scale bar is
5 mm.
doi:10.1371/journal.pone.0054672.g003
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Figure 4. Mannosidase treatment of glycans released from enzymatically untreated HeLa cells. Column height of each individual glycan
group is normalized to the highest one, set to 100 (GP7). Gray column (GP11) represents an internal standard (2-aminobenzamide labeled dextran
peak) added in order to equalize and normalize peak signals, correctly interpret background signals and verify the composition and percentages of
oligomannose structures within these peaks.
doi:10.1371/journal.pone.0054672.g004
Epigenetic Modulation of Membrane N-Glycome
PLOS ONE | www.plosone.org 4 January 2013 | Volume 8 | Issue 1 | e54672
samples. Chromatography peaks were separated in same con-
ditons for both samples.
Treatment with Trichostatin A
Trichostatin A (Sigma) was dissolved in dimethyl sulfoxide at
stock concentration of 1 mg/mL and stored at 220uC until use.
HeLa cells were plated at a density of 6.46105 cells in 6 cm dishes
24 h prior to the treatment with 40 ng/mL TSA. 24 h after the
treatment, the medium was replaced with fresh medium contain-
ing same concentrations of TSA. Cells were either collected and
embedded in polyacrylamide gels 48 h post-treatment or, before
embedding, left to recover in a fresh (drug-free) medium for 24 h
or 5 days.
Treatment with sodium (Na-) butyrate
Na-butyrate (Sigma) was dissolved in Phosphate buffered saline
(PBS) at stock concentration of 0.5 M and stored at 220uC until
use. HeLa cells were plated at a density of 6.46105 cells in 6 cm
dishes 24 h prior to the treatment with 6 mM Na-butyrate. Cells
were either collected and embedded in polyacrylamide gels 24 h
post-treatment or, before embedding, left to recover in a fresh
(drug-free) medium for additional 24 h.
Treatment with zebularine
Zebularine (Sigma) was dissolved in Phosphate buffered saline
(PBS) at a stock concentration of 10 mM and stored at 4uC until
use. HeLa cells were plated at a density of 1.8 or 3.66105 cells in
6 cm dishes 24 h prior to the treatment with 100 mM zebularine.
48 h after the first treatment, the medium was replaced with fresh
medium containing same concentrations of zebularine. Cells were
either collected and embedded in polyacrylamide gels 72 h post-
treatment or, before embedding, left to recover in a fresh (drug-
free) medium for 72 h. Control cells were left untreated.
Data analysis
The surface under each individual chromatographic peak,
representing the contribution of a specific glycan group (GP1–
GP12) in total measured glycans, was expressed as percentages.
Changes in glycan contribution following treatments with diverse
epigenetic inhibitors were normalized to control values, which
were set to 100%.
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Figure 5. Changes in mean contributions of glycan groups GP1, GP5 and GP10 following TSA treatment and recovery. The observed
changes were normalized to control values, which were set to 100%. The error bars represent standard deviations obtained on the basis of 4
independent experiments.
doi:10.1371/journal.pone.0054672.g005
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Figure 6. Changes in mean contributions of glycan groups GP1, GP5 and GP7 following Na-butyrate treatment and recovery. The
observed changes were normalized to control values, which were set to 100%. The error bars represent standard deviations obtained on the basis of
3 independent experiments.
doi:10.1371/journal.pone.0054672.g006
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Figure 7. Changes in mean contribution of the glycan group GP1 following zebularine treatment and recovery. The observed changes
were normalized to control values, which were set to 100%. The error bars represent standard deviations obtained on the basis of 4 independent
experiments.
doi:10.1371/journal.pone.0054672.g007
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Results and Discussion
1. Quantification of glycans from embedded cells
improves reproducibility of the analysis
Following co-polymerization of HeLa cells in the acrylamide
gels, N-glycans were released from the cell surface and labeled with
2-AB. The composition of the membrane glycome was expressed
as the contribution of glycan groups eluted as individual
chromatographic peaks (Fig. 1). In addition to glycan identification
based on GlycoBase (http://glycobase.nibrt.ie) assignment, we
performed exoglycosidase sequencing of the major HPLC peaks to
confirm attributed structures (Fig. S1). Since our previous results
suggested high content of oligomannose structures in the
membrane glycome [31], we treated the sample with the enzyme
mannosidase and confirmed significant contribution of oligoman-
nose glycans to most of the glycan groups (Fig. 1). The effect was
especially remarkable in case of GP5 (biantennary disialylated
glycans with fucosylated core) and GP7 (tetraantennary glycans)
where their relative contributions to the total N-glycome were
reduced from 28,92% to 8,74%, and 12,83% to 4,23%,
respectively. Since oligomannose glycans are involved in protein
folding [42], their role in cancerous cells could easily be associated
with improper maturation of membrane N-glycoproteins, thereby
affecting cellular interactions with the environment. Indeed, it has
been shown that the overexpression of glycoproteins with
oligomannose N-glycans at the cell surface induces proliferative
and adhesive properties of cancer cells and potentially facilitates
loss of contact inhibition, a hallmark feature of majority of cancer
cells [43].
Since glycans can also be obtained following disruption of
cellular integrity, we decided to compare the methodological
precision of N-glycan analysis from embedded cells to the total N-
glycome obtained by the analysis of HeLa cell lysates. The
observed glycan profiles were somewhat different, with particular
glycan groups being selectively more abundant in the lysates or
the embedded cell fraction (Fig. 2A). This is not surprising since
Golgi and ER, which get disrupted during cell lysis, contain high
amounts of both complete and partly synthesized glycans [44]
and these can alter the proportion of a particular glycan group.
Each of the two glycan release methods was repeated six times
to estimate their reproducibility. For nearly all glycan peaks, we
observed higher coefficients of variation when glycome was
analyzed from cell lysates (Fig. 2B). Especially high experimental
variation was observed in highly branched glycan structures
(GP9-GP12), which are important for the regulation of mem-
brane half-life of many receptors [45,46]. This increased
variation of complex structures from experiment to experiment
probably reflects their small contribution to the total glycome.
Since glycans function as regulators of the activity of membrane
proteins, many of them are also attached to proteins on the
luminal side of various cytoplasmic vesicles, including the Golgi
apparatus where posttranslational glycan processing occurs.
Homogenization of cells results in mixing of these two
compartments, containing physiologically separate fractions of
glycans, and consequently leads to masking of relatively subtle,
but functionally important, differences in the cell membrane N-
glycome [45]. Therefore, we believe that the analysis of N-
glycome from embedded cells results in improved analytical
precision due to elimination of the homogenization step from the
procedure. Based on these observations we decided to further
exploit the method of glycan analysis from embedded cells.
2. Glycans extracted from embedded cells preferentially
constitute a cell membrane fraction
To define more accurately the origin of glycan fraction isolated
from the embedded cells, we observed cells following their
embedding into the acrylamide gels by confocal scanning
microscopy. Staining with Ricinus Communis Agglutinin I
confirmed the preserved integrity of the cell membrane during
the embedding process (Fig. 3), thus arguing in favor of glycans
originating mostly from the cell membrane glycoproteins. How-
ever, since we could not exclude the possibility of leakage during
the subsequent steps, we analyzed glycans from embedded cells
that were not treated with PNGase F, in order to release glycans
from glycoproteins. Interestingly, we obtained certain glycan peaks
and attributed those to oligomannose structures, due to an existing
efflux of oligomannose glycans [47]. We validated this hypothesis
by mannosidase treatment, which resulted in almost complete
disappearance of the corresponding chromatographic peaks
(Fig. 4), thus confirming the contribution of free oligomannose
glycans to the pool of glycans released by PNGase F from
glycoproteins associated with the cell membrane. In addition, a
tiny fraction of remaining peaks (GP1 and GP3) could as well
predominantly represent glycan structures transported to the cell
surface unattached to their protein counterparts. Based on the
presented experiments, we conclude that there was no significant
glycan leakage from embedded cells, since the chromatogram
obtained from the analysis of untreated cells did not contain
structures other than the oligomannose.
3. Modulation of the HeLa cell membrane N-glycome by
deacetylase inhibitors Trichostatin A and Na-butyrate
Histone acetylation at gene promoters is an important
epigenetic modification controlling gene expression. Treatment
with the deacetylase inhibitor Trichostatin A resulted in altered
expression of glyco-genes in HepG2 cancer cells [48], whereas
both Trichostatin A and sodium butyrate altered the composition
of glycan structures in HeLa cells [31]. However, whether the
original glycan profile upon drug removal from the medium is
preferentially restored or irreversibly changed is still unknown.
We performed multiple independent experiments wherein,
following the treatments, HeLa cells were left to grow in a drug-
free medium. Major N-glycome changes were not expected since
the inhibition of HDAC activity affects the expression of only 2%
of mammalian genes [49,50]. However, a couple of glycan groups
were affected (Fig. S2). In general, sodium butyrate induced
milder changes than TSA (up to 20% versus up to 40%), probably
due to its lower affinity to bind the substrate [51], requiring higher
concentrations to have an effect [52]. Both inhibitors induced the
increased expression of biantennary glycans (GP1), and the
decreased expression of disialylated glycans with core-fucose
(GP5) (Fig. 5 & 6). Specifically, TSA downregulated the expression
of complex, branched glycan structures from GP10 (Fig. 5),
whereas sodium butyrate upregulated the expression of tetra-
antennary glycans from GP7 (Fig. 6). Since incorporation of fucose
into glycoproteins and increased glycan branching are both
associated with malignant phenotype [53,54], the observed
reduction in quantity of these glycans following an epigenetic
treatment is a desirable effect. However, following cell recovery in
a drug-free medium we observed reversal of the induced effects
and obtained similar composition of the membrane N-glycome of
HeLa cells as prior to the treatments (Fig. 5 & 6). This finding
strongly argues in favor of stability of the N-glycome and
corresponding epigenetic mechanisms responsible for establish-
ment and maintenance of histone acetylation levels of glyco-genes
Epigenetic Modulation of Membrane N-Glycome
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involved in glycan biosynthesis. It also confirms transient mode of
TSA action, based on reversible binding to HDACs [55,56], and
demonstrates the importance of recurrent epigenetic treatments
for successful reversal of potentially undesirable glycan pheno-
types.
4. Modulation of the HeLa cell membrane N-glycome by
zebularine
The role of DNA methylation in the regulation of glycosylation
has particularly been studied in the context of fucosylation, which
is present mostly on secretory or membrane proteins on the cell
surface, such as epidermal growth factor and transforming growth
factor beta receptors [57,58]. Fucosylation levels in normal liver
and colon are relatively low, but increase during carcinogenesis,
mediating killing of oncogenically transformed cells by natural
killer (NK) cells [59]. However, mutations in the gene GMDS
(GDP-mannose-4,6-dehydratase) coding for a key enzyme in-
volved in the synthesis of GDP-fucose, a donor substrate for
fucosyltransferases, further enhance tumor growth due to devel-
oped resistance to NK cells [60]. Therefore, zebularine treatments
of various cancer cell lines with relatively low fucosylation levels
were performed in order to induce up-regulation of fucosylation-
related genes and consequently restore global fucosylation level
[57]. Interestingly, we observed in HeLa cells that the expression
of fucosylated glycans (from GP2-GP6) was not altered following
the 100 mM zebularine treatment (Fig. S2). This finding could
imply either the existence of an alternative fucosylation-indepen-
dent immune-protective mechanism related to cervical carcinoma
or that the fucosylation level itself in HeLa cells is not significantly
lowered as a result of malignant transformation, thus abrogating
the need for its restoration to normal levels. Further insight into
the matter could potentially be gained by investigating mutations
(e.g. in GMDS) and expression levels of fucosylation-related genes
followed by comparison of obtained results between cancerous and
healthy tissue on one hand and cancer cells in culture on the other.
In contrast to mostly unaffected fucosylated glycans, the simplest
biantennary (GP1) glycans were strongly up-regulated following
zebularine treatment (Fig. 7). However, the 72h-recovery in a
drug-free medium resulted in almost complete restoration of
normal values, arguing in favor of reversible covalent association
between the DNMTs and the zebularine-containing DNA [61].
5. Conclusions
Here, we demonstrate the effects of three epigenetic inhibitors
on the composition of N-glycome present preferentially at the
surface of HeLa cells. Interestingly, all of the induced changes
were reversible upon recovery in a drug-free medium. These
observations argue in favor of transient stability of chemical bonds
between the inhibitors and corresponding enzymes whose activity
they abrogate. Since glycans play various important roles during
carcinogenesis, we believe it is necessary to monitor changes in
their expression levels as a result of treatments with epigenetic
inhibitors, of which many are currently under clinical evaluation
as promising antitumor therapeutic agents. Especially important
fraction affecting cellular communication, whereby defining
response to a diseased state/cell, is represented by glycans found
at the cellular surface. Therefore, we argue that thorough
understanding of the response of this glycan fraction to a given
epigenetic treatment is at the basis of a successful medical therapy,
facilitating choice of an adequate drug as well as appropriate
dosage, duration of the treatment and frequency of drug
administration.
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deviations.
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